Amgen Reports 4% Sales Growth in Q1 and Submits Label Update for Autoimmune Drug
Amgen reported a 4% increase in first-quarter sales, driven by strong demand for cholesterol-lowering drugs like Repatha. The company submitted an FDA label update for its autoimmune drug Tavneos amid proposed approval withdrawal due to efficacy concerns.
Tickers: $AMGN
Topics: drug development earnings FDA pharmaceuticals sales